Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BV100 with low-dose polymyxin B plus either ceftazidime/avibactam or cefiderocol for carbapenem-resistant Acinetobacter bauman…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloodstream Infection
• Hospital-acquired Bacterial Pneumonia
• Meningitis Bacterial
• Ventilator-associated Bacterial Pneumonia
• Ventriculitis Infectious

Drugs mentioned

• BV100
• Cefiderocol (cefiderocol)
• POLYMYXIN B (POLYMYXIN B SULFATE)
• ceftazidime/avibactam (ceftazidime/avibactam)

Snippet

Sponsor: BioVersys AG | Conditions: Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP) | Phase 2 | Status: NOT_YET_RECRUITING